ReNeuron

Last updated

ReNeuron
Company typePublic company
LSE:  RENE
IndustryStem cell research & development
Founded1997
Headquarters Surrey, England, UK
Key people
chairman = Trevor Jones
Website reneuron.com

ReNeuron is a UK-based stem cell research company whose shares were listed on the Alternative Investment Market, until it delisted in August 2024 after entering administration. [1] Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.

As of 2010 ReNeuron was testing the effects of neural stem cells on spinal cords for neuroregeneration. [2] They were also testing the use of fetal stem cells on stroke patients. [3]

References

  1. ↑ Life sciences firm ReNeuron to delist as it aims to exit administration - MSN, 30 August 2024
  2. ↑ Cookson, Clive (4 May 2010). "Regenerative medicine: Possibilities multiply for nerve cell regrowth" . Retrieved 23 May 2010.
  3. ↑ "EU agency prepares to assess first stem cell drug". Reuters. 12 May 2010. Retrieved 23 May 2010.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.